首页|Impact of ribavirin dose on retreatment of chronic hepatitis C patients
Impact of ribavirin dose on retreatment of chronic hepatitis C patients
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
AIM:To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients.METHODS:Out of 1228 CHC patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV),165(13％) had a relapse.Among these,62 patients were retreated with PEG-IFN-α2a or-α2b and RBV.Clinical,biological,virological and histological data were collected.Initial doses and treatment modifications were recorded.The efficacy of retreatment and predictive factors for SVR were analyzed.RESULTS:An SVR was achieved in 42％ of patients.SVR was higher in young (＜ 50 years) (61％) than old patients (27％) (P =0.007),and in genotype 2 or 3 (57％) than in genotype 1 or 4 (28％) patients (P=0.023).Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53％ vs 28％,P =0.04).Also,a better SVR rate was observed with RBV dose/body weight ＞ 15.2mg/kg per day (70％ vs 35％,P =0.04).In logistic regression,predictors of a response were age (P =0.018),genotype (P =0.048) and initial RBV dose/body weight (P =0.022).None of the patients without a complete early virological response achieved an SVR (negative predictive value =100％).CONCLUSION:Retreatment with PEG-IFN/RBV is effective in genotype 2 or 3 relapsers,especially in young patients.A high dose of RBV seems to be important for the retreatment response.
NETL
NSTL
万方数据
维普
